Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
4.290
-0.150 (-3.38%)
Nov 21, 2025, 4:00 PM EST - Market closed
Outset Medical Stock Forecast
Stock Price Forecast
The 3 analysts that cover Outset Medical stock have a consensus rating of "Strong Buy" and an average price target of $16, which forecasts a 272.96% increase in the stock price over the next year. The lowest target is $14 and the highest is $17.
Price Target: $16 (+272.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Outset Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 1 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $17 → $14 | Strong Buy | Maintains | $17 → $14 | +226.34% | Nov 11, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $22 → $17 | Hold | Maintains | $22 → $17 | +296.27% | Nov 11, 2025 |
| BTIG | BTIG | Strong Buy Maintains $39 → $17 | Strong Buy | Maintains | $39 → $17 | +296.27% | Nov 11, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $22 | Hold | Reiterates | $22 | +412.82% | Aug 19, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | +412.82% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
127.86M
from 113.69M
Increased by 12.46%
Revenue Next Year
141.30M
from 127.86M
Increased by 10.51%
EPS This Year
-4.43
from -36.95
EPS Next Year
-2.68
from -4.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 130.8M | 147.0M | |||
| Avg | 127.9M | 141.3M | |||
| Low | 121.3M | 131.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.1% | 15.0% | |||
| Avg | 12.5% | 10.5% | |||
| Low | 6.7% | 3.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.10 | -2.26 | |||
| Avg | -4.43 | -2.68 | |||
| Low | -5.18 | -3.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.